Crescent Capital BDC (NASDAQ:CCAP) and BR Biopharma (NASDAQ:BRBI) Head to Head Review

Crescent Capital BDC (NASDAQ:CCAP) and BR Biopharma (NASDAQ:BRBI) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Crescent Capital BDC and BR Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescent Capital BDC	-2.02%	9.02%	3.82%
BR Biopharma	N/A	N/A	N/A

Dividends

Crescent Capital BDC pays an annual dividend of $1.36 per share and has a dividend yield of 15.7%. BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 2.8%. Crescent Capital BDC pays out -1,511.1% of its earnings in the form of a dividend. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Crescent Capital BDC has raised its dividend for 1 consecutive years. Crescent Capital BDC is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

49.5% of Crescent Capital BDC shares are held by institutional investors. 1.2% of Crescent Capital BDC shares are held by company insiders. Comparatively, 29.4% of BR Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Crescent Capital BDC and BR Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Capital BDC	$167.29 million	1.91	$34.51 million	($0.09)	-96.22
BR Biopharma	$2.23 billion	0.08	$31.36 million	$0.08	187.44

Crescent Capital BDC has higher earnings, but lower revenue than BR Biopharma. Crescent Capital BDC is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Crescent Capital BDC and BR Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Capital BDC	0	6	1	0	2.14
BR Biopharma	1	0	0	0	1.00

Crescent Capital BDC currently has a consensus target price of $12.25, suggesting a potential upside of 41.45%. Given Crescent Capital BDC’s stronger consensus rating and higher probable upside, analysts plainly believe Crescent Capital BDC is more favorable than BR Biopharma.

Summary

Crescent Capital BDC beats BR Biopharma on 11 of the 16 factors compared between the two stocks.

About Crescent Capital BDC

Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.